alpha-aminopyridine has been researched along with cyclin d1 in 11 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 11 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Beckmann, RP; Buchanan, SG; Burke, TF; Chan, EM; Huber, L; Peng, SB; Starling, JJ; Van Horn, RD; Yadav, V; Zhang, Y | 1 |
| Chong, Y; Han, Y; Liu, H; Liu, X; Niu, M | 1 |
| Finn, RS; O'Leary, B; Turner, NC | 1 |
| Okamura, H; Sasaki, S; Taniguchi, Y; Wang, L | 1 |
| Blosser, W; Buchanan, S; Dempsey, J; Dowless, M; Ebert, P; Flack, R; Gong, X; Gupta, S; Houghton, P; Iversen, P; Lowery, CD; Olsen, JB; Renschler, M; Shackleford, T; Stancato, L; Stephens, J; Stewart, J; VanWye, AB; Webster, Y | 1 |
| Dickmanns, A; Dobbelstein, M; Johnsen, SA; Najafova, Z; Sriraman, A | 1 |
| Ailles, L; Bratman, SV; Bruce, JP; Erdmann, N; Goldstein, DP; Hope, AJ; Huang, SH; Hyatt, E; Karamboulas, C; Liu, FF; Meens, J; O'Sullivan, B; Pereira, K; Pugh, TJ; Su, J; Tiedemann, R; Weinreb, I; Xu, W | 1 |
| Abedini, A; Auguste, A; Bertos, N; Cencic, R; Chen, H; Clarke, BA; de Rink, I; Dostie, J; Firlit, M; Foulkes, WD; Gotlieb, WH; Guiot, MC; Hass, R; Huang, S; Jelinic, P; Johnson, RM; Judkins, AR; Kerkhoven, RM; Kong, T; Leary, A; Levine, DA; Macdonald, E; Martinez, D; Meehan, B; Morin, G; Papadakis, AI; Park, M; Patibandla, J; Pelletier, J; Rak, J; Vanderhyden, B; Venneti, S; Wang, XQD; Witcher, M; Witkowski, L; Xue, Y | 1 |
| Arteaga, CL; Balko, JM; Bardia, A; Bauer, JA; Behdad, A; Cristofanilli, M; Croessmann, S; Cruz, MR; Dugger, TC; Ericsson, PG; Formisano, L; Guerrero-Zotano, AL; Guo, Y; Hanker, AB; He, W; Jansen, VM; Lanman, RB; Lee, KM; Lu, Y; Mayer, IA; Miller, M; Nagy, RJ; Nixon, MJ; O'Shaughnessy, J; Sanders, ME; Schwarz, LJ; Servetto, A; Shyr, Y; Solovieff, N; Su, F; Sudhan, DR | 1 |
| Yardley, DA | 1 |
| Chen, F; Li, T; Wang, Q; Wang, Y; Xiong, Y; Yu, X; Zeng, Y; Zhou, F; Zhou, Y | 1 |
1 review(s) available for alpha-aminopyridine and cyclin d1
| Article | Year |
|---|---|
Treating cancer with selective CDK4/6 inhibitors.
Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Breast Neoplasms; Cell Cycle; Clinical Trials as Topic; Cyclin D1; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Female; Forecasting; Humans; Molecular Targeted Therapy; Neoplasms; Piperazines; Purines; Pyridines | 2016 |
1 trial(s) available for alpha-aminopyridine and cyclin d1
| Article | Year |
|---|---|
MONALEESA clinical program: a review of ribociclib use in different clinical settings.
Topics: Adolescent; Adult; Aminopyridines; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Cyclin D1; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Estrogens; Female; Fulvestrant; Humans; Letrozole; Middle Aged; Postmenopause; Progression-Free Survival; Purines; Receptor, ErbB-2; Tamoxifen; Young Adult | 2019 |
9 other study(ies) available for alpha-aminopyridine and cyclin d1
| Article | Year |
|---|---|
The CDK4/6 inhibitor LY2835219 overcomes vemurafenib resistance resulting from MAPK reactivation and cyclin D1 upregulation.
Topics: Aminopyridines; Animals; Apoptosis; Benzimidazoles; Cell Line, Tumor; Cell Proliferation; Cyclin D1; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Drug Resistance, Neoplasm; Female; Humans; Indoles; MAP Kinase Signaling System; Mice; Mice, Nude; Protein Kinase Inhibitors; Signal Transduction; Sulfonamides; Transfection; Up-Regulation; Vemurafenib; Xenograft Model Antitumor Assays | 2014 |
Novel reversible selective inhibitor of CRM1 for targeted therapy in ovarian cancer.
Topics: Aminopyridines; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cyclin B; Cyclin D1; Cyclopentanes; Exportin 1 Protein; Female; Gene Expression Regulation, Neoplastic; Humans; Karyopherins; Ovarian Neoplasms; Receptors, Cytoplasmic and Nuclear | 2015 |
Modification of the aminopyridine unit of 2'-deoxyaminopyridinyl-pseudocytidine allowing triplex formation at CG interruptions in homopurine sequences.
Topics: Aminopyridines; Base Composition; Base Pairing; Base Sequence; Binding Sites; Cell-Free System; Cyclin D1; Deoxycytidine; DNA; Gene Expression Regulation; Humans; Kinetics; Models, Molecular; Nucleosides; Promoter Regions, Genetic; Purines; Telomerase | 2018 |
Abemaciclib Is Active in Preclinical Models of Ewing Sarcoma via Multipronged Regulation of Cell Cycle, DNA Methylation, and Interferon Pathway Signaling.
Topics: Aminopyridines; Animals; Benzimidazoles; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cyclin D1; Disease Models, Animal; DNA (Cytosine-5-)-Methyltransferase 1; DNA Methylation; Drug Evaluation, Preclinical; Drug Resistance, Neoplasm; Humans; Interferons; Mice; Sarcoma, Ewing; Signal Transduction; Xenograft Model Antitumor Assays | 2018 |
CDK4 inhibition diminishes p53 activation by MDM2 antagonists.
Topics: Aminopyridines; Antineoplastic Agents; Benzimidazoles; Cell Line, Tumor; Cell Proliferation; Cyclin D1; Cyclin-Dependent Kinase 4; Humans; Piperazines; Proto-Oncogene Proteins c-mdm2; Purines; Pyridines; RNA Interference; RNA, Small Interfering; Sarcoma; Tumor Suppressor Protein p53 | 2018 |
Patient-Derived Xenografts for Prognostication and Personalized Treatment for Head and Neck Squamous Cell Carcinoma.
Topics: Aminopyridines; Animals; Base Sequence; Benzimidazoles; Cyclin D1; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Cyclin-Dependent Kinase Inhibitor p16; Female; Humans; Male; Mice, Inbred NOD; Mice, SCID; Middle Aged; Multivariate Analysis; Mutation; Neoplasm Recurrence, Local; Precision Medicine; Prognosis; Regression Analysis; Risk Factors; Squamous Cell Carcinoma of Head and Neck; Survival Analysis; Treatment Outcome; Xenograft Model Antitumor Assays | 2018 |
CDK4/6 inhibitors target SMARCA4-determined cyclin D1 deficiency in hypercalcemic small cell carcinoma of the ovary.
Topics: Aminopyridines; Animals; Benzimidazoles; Carcinoma, Small Cell; Cell Line, Tumor; Cell Survival; Chromatin Immunoprecipitation; Cyclin D1; DNA Helicases; Female; Humans; Hypercalcemia; Mice; Mice, SCID; Nuclear Proteins; Ovarian Neoplasms; Piperazines; Protein Kinase Inhibitors; Purines; Pyridines; RNA, Small Interfering; Transcription Factors | 2019 |
Aberrant FGFR signaling mediates resistance to CDK4/6 inhibitors in ER+ breast cancer.
Topics: Aminopyridines; Animals; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Circulating Tumor DNA; Cyclin D1; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Drug Resistance, Neoplasm; Female; Fulvestrant; High-Throughput Nucleotide Sequencing; Humans; MCF-7 Cells; Mice; Mutation; Naphthalenes; Piperazines; Progression-Free Survival; Proportional Hazards Models; Protein Kinase Inhibitors; Purines; Pyrazoles; Pyridines; Quinolines; Quinoxalines; Receptor, Fibroblast Growth Factor, Type 1; Receptor, Fibroblast Growth Factor, Type 2; Receptors, Estrogen; Signal Transduction; Xenograft Model Antitumor Assays | 2019 |
Ribociclib (LEE011) suppresses cell proliferation and induces apoptosis of MDA-MB-231 by inhibiting CDK4/6-cyclin D-Rb-E2F pathway.
Topics: Aminopyridines; Animals; Apoptosis; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cyclin D1; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Cyclin-Dependent Kinase Inhibitor Proteins; E2F1 Transcription Factor; Female; Humans; Male; Mammary Neoplasms, Experimental; Mice; Mice, Nude; Phosphorylation; Purines; Retinoblastoma Protein; Triple Negative Breast Neoplasms; Tumor Burden | 2019 |